Drugs / VERVE-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06451770 | Oct 2024 → Dec 2027 expected | hyperlipidemia, hypertriglyceridemia | Verve Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-03 | Verve Therapeutics, Inc. | Results Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates vervetx.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-03 | Verve Therapeutics, Inc. | Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates vervetx.com ↗ |
| 2022-08-09 | Verve Therapeutics, Inc. | Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress vervetx.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VERVE-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06451770 ↗ |
| Action | Inhibit | “inactivate the expression of the ANGPTL3 gene” NCT06451770 ↗ |
| Modality | CRISPR / gene editing | “VERVE-201 uses base-editing technology” NCT06451770 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT06451770 ↗ |
| Target | ANGPTL3 | “inactivate the expression of the ANGPTL3 gene” NCT06451770 ↗ |